阿法替尼-话题@MedSci

#阿法替尼#

1篇内容 | 2021人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2261814, encodeId=1e542261814c7, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=e5429e857f7' target=_blank style='color:#2F92EE;'>#阿法替尼#</a>, objectTitle=JCO：无进展生存期几乎翻倍，阿法替尼或改写这类肺癌治疗标准, objectType=article, longId=872961, objectId=076f8e29611f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250121/1737454189523_8538692.png, objectUrl=/article/show_article.do?id=076f8e29611f, replyNumber=0, likeNumber=26, createdTime=2025-04-24, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=076f8e29611f, moduleTitle=JCO：无进展生存期几乎翻倍，阿法替尼或改写这类肺癌治疗标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=076f8e29611f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2247504, encodeId=b501224e504fa, content=<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a> <a href='/topic/show?id=e5429e857f7' target=_blank style='color:#2F92EE;'>#阿法替尼#</a> <a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a>, objectTitle=G719X、L861Q等罕见EGFR突变晚期NSCLC一线治疗，阿法替尼和奥希替尼优于化疗和一代TKI, objectType=article, longId=858981, objectId=24f285898176, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/young-people-on-medical-staff-meeting-ZFY96R4.jpg, objectUrl=/article/show_article.do?id=24f285898176, replyNumber=0, likeNumber=55, createdTime=2025-01-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=24f285898176, moduleTitle=G719X、L861Q等罕见EGFR突变晚期NSCLC一线治疗，阿法替尼和奥希替尼优于化疗和一代TKI, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24f285898176)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2226851, encodeId=c3db2226851d3, content=<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a> <a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a> <a href='/topic/show?id=e5429e857f7' target=_blank style='color:#2F92EE;'>#阿法替尼#</a> <a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a>, objectTitle=奥希替尼vs阿法替尼或厄洛替尼，“谁”在非典型EGFR突变转移性NSCLC中更胜一筹, objectType=article, longId=844005, objectId=2fb68440054c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240802/1722564816714_8538692.png, objectUrl=/article/show_article.do?id=2fb68440054c, replyNumber=0, likeNumber=96, createdTime=2024-09-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=2fb68440054c, moduleTitle=奥希替尼vs阿法替尼或厄洛替尼，“谁”在非典型EGFR突变转移性NSCLC中更胜一筹, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fb68440054c)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2214253, encodeId=db09221425334, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a> <a href='/topic/show?id=e5429e857f7' target=_blank style='color:#2F92EE;'>#阿法替尼#</a> <a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a>, objectTitle=李艳：EGFR少见突变非小细胞肺癌需探寻更加精准的诊疗, objectType=article, longId=833763, objectId=21b4833e6364, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240710/1720582603558_1608702.jpg, objectUrl=/article/show_article.do?id=21b4833e6364, replyNumber=0, likeNumber=132, createdTime=2024-07-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=21b4833e6364, moduleTitle=李艳：EGFR少见突变非小细胞肺癌需探寻更加精准的诊疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21b4833e6364)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2214204, encodeId=8daa2214204b6, content=<a href='/topic/show?id=b860101129ac' target=_blank style='color:#2F92EE;'>#食管鳞状细胞癌#</a> <a href='/topic/show?id=e5429e857f7' target=_blank style='color:#2F92EE;'>#阿法替尼#</a> <a href='/topic/show?id=2d231164e0ea' target=_blank style='color:#2F92EE;'>#EGFR过表达#</a>, objectTitle=STTT | 阿法替尼治疗EGFR过表达食管鳞状细胞癌的疗效评估, objectType=article, longId=833835, objectId=913183383503, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240710/1720578072252_92910.jpg, objectUrl=/article/show_article.do?id=913183383503, replyNumber=0, likeNumber=132, createdTime=2024-07-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=913183383503, moduleTitle=STTT | 阿法替尼治疗EGFR过表达食管鳞状细胞癌的疗效评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=913183383503)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2189644, encodeId=02e8218964480, content=<a href='/topic/show?id=13db460162d' target=_blank style='color:#2F92EE;'>#实体瘤#</a> <a href='/topic/show?id=e5429e857f7' target=_blank style='color:#2F92EE;'>#阿法替尼#</a> <a href='/topic/show?id=bdb811161043' target=_blank style='color:#2F92EE;'>#神经调节蛋白1#</a>, objectTitle=真实世界数据：NRG1融合阳性实体瘤患者阿法替尼治疗的临床结局, objectType=article, longId=814877, objectId=d76e8148e755, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-is-working-at-the-hospital-P9JMZYE.jpg, objectUrl=/article/show_article.do?id=d76e8148e755, replyNumber=0, likeNumber=124, createdTime=2024-02-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d76e8148e755, moduleTitle=真实世界数据：NRG1融合阳性实体瘤患者阿法替尼治疗的临床结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d76e8148e755)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2183936, encodeId=9a872183936b8, content=<a href='/topic/show?id=211e823029d' target=_blank style='color:#2F92EE;'>#肺腺癌#</a> <a href='/topic/show?id=e5429e857f7' target=_blank style='color:#2F92EE;'>#阿法替尼#</a> <a href='/topic/show?id=a20e45830e0' target=_blank style='color:#2F92EE;'>#安罗替尼#</a>, objectTitle=EGFR突变状态大变样导致三代TKI耐药，阿法替尼+安罗替尼稳定病情, objectType=article, longId=810875, objectId=5b988108e5cf, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016274166_4754896.png, objectUrl=/article/show_article.do?id=5b988108e5cf, replyNumber=0, likeNumber=119, createdTime=2024-01-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=5b988108e5cf, moduleTitle=EGFR突变状态大变样导致三代TKI耐药，阿法替尼+安罗替尼稳定病情, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b988108e5cf)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1242695, encodeId=f7e01242695c7, content=<a href='/topic/show?id=f31f39333f0' target=_blank style='color:#2F92EE;'>#吴一龙#</a>教授IIIb期研究关注近<a href='/topic/show?id=44cee263861' target=_blank style='color:#2F92EE;'>#真实世界研究#</a>中afatinib(<a href='/topic/show?id=e5429e857f7' target=_blank style='color:#2F92EE;'>#阿法替尼#</a>)治疗EGFR突变阳性<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a>患者的疗效 , objectTitle=Target Oncol:吴一龙教授IIIb期研究关注近真实世界中afatinib(阿法替尼)治疗EGFR突变阳性NSCLC患者的疗效, objectType=article, longId=295658, objectId=04a8295658c9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2022214/1644842572252_1611618.PNG, objectUrl=/article/show_article.do?id=04a8295658c9, replyNumber=0, likeNumber=206, createdTime=2022-09-02, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04a8295658c9, moduleTitle=Target Oncol:吴一龙教授IIIb期研究关注近真实世界中afatinib(阿法替尼)治疗EGFR突变阳性NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04a8295658c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

阿法替尼

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#肺癌# #阿法替尼#

JCO：无进展生存期几乎翻倍，阿法替尼或改写这类肺癌治疗标准

2025-04-24发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#NSCLC# #阿法替尼# #奥希替尼#

G719X、L861Q等罕见EGFR突变晚期NSCLC一线治疗，阿法替尼和奥希替尼优于化疗和一代TKI

2025-01-10发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#NSCLC# #厄洛替尼# #阿法替尼# #奥希替尼#

奥希替尼vs阿法替尼或厄洛替尼，“谁”在非典型EGFR突变转移性NSCLC中更胜一筹

2024-09-21发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #EGFR# #阿法替尼# #奥希替尼#

李艳：EGFR少见突变非小细胞肺癌需探寻更加精准的诊疗

2024-07-10发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#食管鳞状细胞癌# #阿法替尼# #EGFR过表达#

STTT | 阿法替尼治疗EGFR过表达食管鳞状细胞癌的疗效评估

2024-07-10发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#实体瘤# #阿法替尼# #神经调节蛋白1#

真实世界数据：NRG1融合阳性实体瘤患者阿法替尼治疗的临床结局

2024-02-27发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#肺腺癌# #阿法替尼# #安罗替尼#

EGFR突变状态大变样导致三代TKI耐药，阿法替尼+安罗替尼稳定病情

2024-01-25发表于陕西省

小小医者 (审核中...)

前往app查看评论内容

#吴一龙#教授IIIb期研究关注近#真实世界研究#中afatinib(#阿法替尼#)治疗EGFR突变阳性#NSCLC#患者的疗效

Target Oncol:吴一龙教授IIIb期研究关注近真实世界中afatinib(阿法替尼)治疗EGFR突变阳性NSCLC患者的疗效

2022-09-02

科室
- - 订阅+
  - 更多科室
工具
服务